Yiangou, Andreas http://orcid.org/0000-0001-8905-5734
Mollan, Susan P. http://orcid.org/0000-0002-6314-4437
Sinclair, Alexandra J. http://orcid.org/0000-0003-2777-5132
Article History
Accepted: 11 October 2023
First Online: 13 November 2023
Competing interests
: A.Y. declares speaker fees from TEVA UK, 2020; grants/funding for a fellowship from the Association of British Neurologists and Guarantors of the Brain. S.P.M. is a member of the advisory boards for Invex Therapeutics (2020/2021/2022) and Gensight (2022) and declares consultant fees from Invex Therapeutics (Trial Steering Group and Independent Adjudication Committee Fees 2022) and the Velux Foundation (2021), speaker fees from Heidelberg Engineering (2020/2021/2022), Chugai (2021/2022), and Chiesi (2020/2021), royalties/licenses from Springer Publishing: <i>Neuro-Ophthalmology</i> — <i>Global Trends in Diagnosis, Treatment and Management</i>. S.P.M. also declares membership of the following organizational arms, without re-imbursement: North American Neuro-Ophthalmology Society (Abstract Committee, Membership Committee, International Relations Committee), UK Neuro-Ophthalmology Society (Secretary), British Isles Neuro-Ophthalmology Club (Treasurer), and United Kingdom Cerebrospinal Fluid Annual Meeting (Convener), and is a member of the editorial boards for <i>Eye</i> (Nature Portfolio) and <i>Journal of Neuro-Ophthalmology</i> (Springer). A.J.S. declares personal fees, share options and shareholding from Invex therapeutics, speaker fees from Allergan-AbbVie, Novartis and Teva UK, other fees from Amgen, Chiesi and Lundbeck, and grants/funding for research studies from the National Institute for Health Research, Medical Research Council, Sir Jules Thorn Trust, and the UK Space Agency.